Symptomatic treatment of occasional heartburn.
Indications
Gaviscon neutralises excess stomach acid and forms a protective barrier that floats on the stomach contents, preventing their reflux.
Strawberry flavour.
Composition
Active ingredients
One tablet contains: Active ingredients: sodium alginate 250 mg; sodium bicarbonate 133.5 mg.
Excipient with known effect: aspartame 8.80 mg.
Excipients
Xylitol, mannitol (E421), calcium carbonate, macrogol 20,000, strawberry flavouring, aspartame (E951), magnesium stearate, red iron oxide.
Directions for use and dosage
Adults and adolescents (12–18 years): 1–2 tablets of 500 mg + 267 mg after meals and at bedtime. 2–4 tablets of 250 mg + 133.5 mg after meals and at bedtime.
Method of administration: For oral administration. The tablets must be chewed well (they can be broken and chewed a little at a time). You can then drink some water.
Special populations:
Elderly:It is not necessary to modify the doses for this age group.
Patients with renal insufficiency: The reduced ability to eliminate the exogenous saline supplement provided by antacids in the urine can cause potentially serious electrolyte imbalances.
Warnings
Do not use for prolonged treatment. In adolescents (12–18 years), use only if clearly needed and under strict medical supervision. Renal insufficiency In case of renal insufficiency, the medicine must be used with caution since the exogenous saline supplement provided by antacids can cause potentially serious electrolyte imbalances.
Each 250 mg + 133.5 mg tablet contains 61.5 mg (2.65 mmol) sodium.
This should be taken into consideration if a particularly low-salt diet is recommended, for example in some cases of congestive heart failure and renal impairment.
Each 250 mg + 133.5 mg tablet contains 80 mg (0.8 mmol) calcium carbonate.
Caution should be exercised when treating patients with hypercalcaemia, nephrocalcinosis, and recurrent calcium-containing renal stones.
The tablets contain aspartame, a source of phenylalanine: it should therefore not be taken by patients with phenylketonuria.
Duration of treatment: If symptoms do not improve after seven days, the clinical picture should be re-evaluated.
Contraindications
Hypersensitivity to the active substances or to any of the excipients.
Interactions
It is advisable to leave an interval of at least two hours between taking Gaviscon and that of other drugs, especially tetracyclines, fluoroquinolones, iron salts, thyroid hormones, chloroquine, bisphosphonates and estramustine.
Undesirable effects
The following are the undesirable effects of Gaviscon, organised according to the MedDRA system organ classification.
They are divided by frequency (very common (? 1/10), common (? 1/100 to ? 1/10), uncommon (? 1/1,000 to ? 1/100), rare (? 1/10,000 to 1/1,000), very rare (? 1/10,000)).
| System Organ Class | Frequency | Adverse Reaction |
| Immune system disorders | Very rare | Anaphylactic or anaphylactoid reactions. Hypersensitivity reactions (such as urticaria). |
| Respiratory, thoracic and mediastinal disorders | Very rare | respiratory symptoms such as bronchospasm |
| Gastrointestinal disorders | Very rare | flatulence, nausea |
| General disorders and administration site conditions | Very rare | oedema |
Overdose
Experience with overdose is very limited.
The only possible consequence of overdose is abdominal distension: in this case, resort to symptomatic treatment and adopt general supportive measures.
Pregnancy and breastfeeding
Use only if clearly needed and under strict medical supervision.
Storage
Do not store above 25°C.
Store in the original packaging.
Format
24 tablets
Product Code:FRCM046109
Richiedi info sul prodotto
